Market Reports

Immunotherapy: antibody drug conjugates from a small molecule perspective

Immunotherapies such as ADCs deliver a more targeted treatment against cancer that improves the quality of life for the patient compared with traditional chemotherapies, write Maurits Janssen, Senior Director, Strategic Business Development, and Bernhard Stump, Associate Director, Head of Process Development Bioconjugates, Lonza Pharma & Biotech

API sourcing: what to look for in a supplier

Jonathan Knight, Director of Market Intelligence and New Technologies at Cambrex, presents an overview of the API sourcing marketplace, summarising the factors that need to be considered when choosing an API supplier in the light of recent global market, political and economic developments

From the lab to the last mile: optimising the pharma cold chain (part I)

With more than 40 COVID-19 vaccines in human testing worldwide and an expected 14 billion vaccines needed to facilitate a global vaccination, the stakes are high when it comes to safe storage and distribution. Dr Kevin Robinson recently caught up with Stirling Ultracold’s CEO, Dusty Tenney, and Robin Grimwood, President and COO of Infinity Biologix, to discuss the criticality of ULT storage as we approach a vaccine delivery date

Model-based optimisation of mixed solvent systems for spray drying

Spray drying is a common and effective approach to enhance the bioavailability of low-solubility small molecules. As the process requires intimate knowledge of aspects such as droplet trajectories, in this article Jonathan L. Cape, Kimberly B. Shepard and Michael M. Morgen, from Lonza Pharma & Biotech, examine different approaches to spray drying and ways to optimise drug production and quality

Developing innovative antivirals for novel viruses

Since the emergence of COVID-19, researchers worldwide have striven to study and overcome this new disease and the novel coronavirus (SARS-CoV-2) that causes it. To achieve this, we will probably need both vaccines and antiviral drugs, report Zamas Lam, Senior Vice President of Preclinical Development, and John Kolman, Vice President of Translational Medicine, QPS

Scaling-up the pharmaceutical supply chain with digitisation: part I

If there are issues with any vaccine, the traditional recall process, which is highly dependent on manual and paper-based processes — and provides no insight in terms of where the product ends up — is not up to the task. It is simply too slow and ill-informed to combat the fallout!

Cleanroom Conference and Manufacturing Chemist Live 2020 to go virtual

The virtual event taking place on 10-11 November 2020 will provide delegates with full access to the Manufacturing Chemist Live, Cleanroom UK, India and Singapore content and exhibitors

Transporting the COVID-19 vaccine around the world: a global problem

Elisabeth Vachette, Head of Product Management for Bags/Mixing/Tanks at Sartorius Stedim Biotech, discusses the challenges associated with distributing a vaccine to the global population with Dr Kevin Robinson

Manufacturing pressure accelerates move to fully formulated film coatings

Why now is the right time to change to a leaner system, explains Colorcon's Dr Jason Teckoe, Technical Director, EMEA

Small test efforts for large production facilities

Sanofi uses filling and closing machines from Syntegon Technology to determine the ideal manufacturing parameters for the development and lifecycle management of its products, explains Sebastian Lauterbach, Area Sales Manager, Syntegon Technology

Cleanroom Conference and Manufacturing Chemist Live events set to go ahead

The co-located events will go ahead in October with new safety measures in place, after being postponed from their original date at the start of summer due to COVID-19

Delivering success for inhaled drug development programmes

No two inhaled drug development programmes will have exactly the same characteristics or drivers; so, to ensure the greatest chance of success, it is important not to be unduly influenced by previous programme, or have a technology bias towards a single platform

Next-generation rapid transfer systems for the biopharmaceutical industry

The safe manufacture of pharmaceutical drugs requires perfectly sterile and particle-free environments. A rapid transfer port, which comprises double containment doors that are integrated into an isolator, is a system that allows the safe transfer of substances used in drug development, such as active pharmaceutical ingredients or vaccines

Overcoming the excipient challenge with a multifunctional filler-binder

Dr Maj-Britt Cepok, Head of Business Development Pharma at BENEO, talks to Dr Kevin Robinson about trends in excipients and explains why the right filler-binder can make all the difference

Isolator transfer design for ATMP products

A challenge posed by the increase of closed systems is the transfer of semi-finished products without losing the aseptic conditions required by regulations. A new study has tested a transfer system aiming to offer biocontainment without losing cell viability of ATMP products

Enhancing clinical trial supply with JTM: part II

In a constantly changing world, the pharmaceutical industry is having to adopt its practices to serve the needs of a rapidly growing and ageing population and develop innovative personalised medicines. Almac has responded to these demands with a Just-in-Time Manufacturing solution that fulfils the requirements of a high value, time sensitive clinical supply chain. Dr Kevin Robinson spoke to Natalie Balanovsky, Just-in-Time Manufacturing Solutions Manager, and Mark Rohlfing, Vice President of Operations, to find out more

Next-generation pharmaceutical spray drying

Lonza's Kimberly B. Shepard, Associate Principal Engineer, and Michael M. Morgen, Associate Director, R&D, discuss mechanistic process development with high-performance polymers for bioavailability enhancement

Reading and understanding vendor-supplied tablet drawings

Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company

Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain

The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA

A pivotal time for pharma's global biotechnology industry

In these uncertain times, GEA, the globally active mechanical and plant engineering company, is taking its role in the fight against the coronavirus — and any other — epidemic, extremely seriously. Committed to “Engineering for a better world,” GEA designs and builds modular plant and fully integrated systems help to bring new treatments to market in the shortest possible time

Accelerating vaccine development with AI

Despite the tremendous advances in medical science in recent decades, there is still so much about the human body that we’re yet to discover, reports Billy Sisk, Life Sciences Industry Manager, EMEA, Rockwell Automation

How to comply with FDA-imposed nitrosamine impurity testing

The detection of nitrosamine impurities in commercially available drugs has recently prompted the US FDA to issue multiple product recalls and mandate additional testing to safeguard consumer health and safety; Michael Walker, Technical Expert at Intertek Pharmaceutical Services, and Jon Bardsley, Vertical Marketing Specialist, Pharma and BioPharma, Thermo Fisher Scientific, report

Excipient innovation for enhanced patient compliance: part II

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Future-proof DMPK studies for next-generation therapeutics

SCIEX's Lei Xiong, Rolf Kern and Elliott Jones explain the top five reasons why you can’t count on ligand-binding assays to study the drug metabolism and pharmacokinetics of biologics

Trending Articles

  1. The economic advantages of continuous flow chemistry Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
  2. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  3. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  4. Poolbeg granted FDA Orphan Drug Designation for POLB 001 The US FDA grants orphan status to support the development of medicines for rare disorders affecting fewer than 200,000 people in the US
  5. Rare diseases: understanding the patient journey In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

Upcoming event

BIO International Convention

3-6 June, 2024 | Convention | Boston, US See all